FTC OKs Teva-Barr Pharma Merger

WASHINGTON (CN) – Teva Pharmaceuticals will buy rival generic drugmaker Barr Pharmaceuticals for $8.9 billion, but the merger partners will have to sell assets in 29 U.S. markets to competitors Watson and Qualitest Pharmaceuticals, the FTC said in a settled complaint. Teva and Barr will have to sell assets that include generic drugs used to treat acid reflux, cancer, bacterial infections, diabetes and depression.